Department of Psychology, Louisiana State University, Baton Rouge, LA 70803, USA.
J Addict Med. 2013 Jan-Feb;7(1):17-24. doi: 10.1097/ADM.0b013e3182738655.
To estimate the prevalence of self-reported substance use and psychiatric disorders in a highly select chronic nonmalignant pain population within a nonprimary care tertiary referral-only pain clinic.
A retrospective, cross-sectional study was accomplished via existing medical record review for 216 consecutive pain patients presenting to an independent neurodiagnostic clinic located in the southeastern United States, specializing in chronic, severe, and complex industrial injuries (e.g., multiple failed fusions, neuropathic pain), involving complex combinations of nocioceptive, neuropathic, and myofascial pain. De-identified self-report data from the Comprehensive Assessment and Psychological Evaluation (a structured diagnostic assessment interview compatible with DSM-IV-TR criteria, which assesses for symptoms of 8 Axis I and 6 Axis II disorders including substance-specific dependence and abuse) were obtained as part of the standard intake procedures for diagnostic determinations. Diagnostic assessment of substance use disorders was also independently verified by a physician certified by the American Society of Addiction Medicine.
An extremely low prevalence of substance abuse and dependence diagnoses were found for 1.9% of the population, of which nearly 30% were not currently prescribed opioid medications for pain. One case of alcohol dependence and 3 cases of alcohol abuse were found. Psychiatric diagnoses, excluding substance use disorders, predominated as follows: major depressive disorder, 44.4%; posttraumatic stress disorder, 29.2%; and obsessive-compulsive personality disorder, 62.5%.
Certain populations of patients with complex nocioceptive, neuropathic, and myofascial pain syndromes may have a lower prevalence of substance use disorders than the general population. They also may have concurrent psychiatric disorders, which should be evaluated and treated concomitantly as part of their chronic pain treatment. Rates reported for possible obsessive-compulsive personality disorder may be reflective of patients' expected preoccupation with pain complaints. The low prevalence of substance use disorders may be attributable to the severity of their illness, the patients' inability to achieve pain relief and obtain pain medications easily, as well as their persistence in pursuing accurate diagnoses and treatment. Roughly one-third were not currently prescribed opioids at the time of the study, perhaps undercutting risk for opioid use disorder rates. Additionally, due to the tertiary referral nature of this clinic, patients with behaviors believed to be a manifestation of opioid use disorder may have already been selected out prior to referral to this clinic. A major limitation of this study was that it relied on a self-report assessment instrument and there were no drug screen findings to report. Such unique clinic characteristics and study limitations may narrow generalizability of results. Despite the low prevalence of substance use disorders observed for this clinic population, these patients must be continuously monitored for abuse, misuse, and diversion of their medication.
在一家非初级保健的三级转诊疼痛诊所中,对高度选择的慢性非恶性疼痛人群进行自我报告的物质使用和精神障碍患病率评估。
通过对 216 名连续的疼痛患者进行现有病历回顾,完成了一项回顾性、横断面研究,这些患者就诊于美国东南部的一家独立神经诊断诊所,该诊所专门治疗慢性、严重和复杂的工业损伤(例如,多次失败的融合、神经性疼痛),涉及痛觉感受、神经性和肌筋膜疼痛的复杂组合。从综合评估和心理评估(与 DSM-IV-TR 标准兼容的结构化诊断评估访谈,评估 8 个轴 I 和 6 个轴 II 障碍的症状,包括物质特异性依赖和滥用)中获得了作为诊断确定标准摄入程序一部分的去识别自我报告数据。物质使用障碍的诊断评估也由美国成瘾医学协会认证的医生独立验证。
人群中发现物质滥用和依赖诊断的患病率极低,为 1.9%,其中近 30%的人目前未开具阿片类药物治疗疼痛。发现 1 例酒精依赖和 3 例酒精滥用。除物质使用障碍外,精神病诊断居多,如下所示:重度抑郁症,44.4%;创伤后应激障碍,29.2%;强迫性人格障碍,62.5%。
某些患有复杂痛觉感受、神经性和肌筋膜疼痛综合征的患者群体的物质使用障碍患病率可能低于一般人群。他们也可能同时患有精神障碍,应作为其慢性疼痛治疗的一部分进行评估和治疗。可能强迫症人格障碍的报告率可能反映了患者对疼痛投诉的预期关注。物质使用障碍的低患病率可能归因于他们疾病的严重程度、他们无法轻易获得疼痛缓解和获得疼痛药物的能力,以及他们坚持寻求准确诊断和治疗的意愿。大约三分之一的人在研究时没有开阿片类药物,这可能降低了阿片类药物使用障碍的发生率。此外,由于该诊所是三级转诊性质,因此在转介到该诊所之前,可能已经将被认为是阿片类药物使用障碍表现的患者筛选掉了。本研究的一个主要限制是它依赖于自我报告评估工具,没有药物检测结果报告。这种独特的诊所特征和研究限制可能会限制结果的普遍性。尽管观察到该诊所人群的物质使用障碍患病率较低,但必须持续监测这些患者的滥用、误用和药物转移情况。